Molecular Determinants of Human T-lymphotropic Virus Type 1 Transmission and Spread by Lairmore, Michael D. et al.
Viruses 2011, 3, 1131-1165; doi:10.3390/v3071131 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
Molecular Determinants of Human T-lymphotropic Virus  
Type 1 Transmission and Spread 
Michael D. Lairmore 
1,2,*, Rajaneesh Anupam 
1, Nadine Bowden 
1, Robyn Haines 
1,  
Rashade A. H. Haynes II 
1, Lee Ratner 
3 and Patrick L. Green 
1,2 
1  Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA;  
E-Mails: anupam.1@osu.edu (R.A.); nyb_dvm@yahoo.com (N.B.); haines.106@osu.edu (R.H.); 
rashade23@sbcglobal.net (R.A.H.H.); green.466@osu.edu (P.L.G.) 
2  Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Solove Research 
Institute, The Ohio State University, Columbus, OH 43210, USA 
3  Department of Medicine, Pathology, and Molecular Microbiology, Division of Biology and 
Biological Sciences, Washington University School of Medicine, Campus Box 8069, 660 S.  
Euclid Ave., St. Louis, MO 63110, USA; E-Mail: lratner@im.wustl.edu (L.R.) 
*  Author to whom correspondence should be addressed; E-Mail: Lairmore.1@osu.edu;  
Tel.: +1-614-292-9203; Fax: +1-614-292-6473.  
Received: 9 May 2011; in revised form: 1 July 2011 / Accepted: 2 July 2011 /  
Published: 12 July 2011 
 
Abstract: Human T-lymphotrophic virus type-1 (HTLV-1) infects approximately 15 to 20 
million people worldwide, with endemic areas in Japan, the Caribbean, and Africa. The 
virus is spread through contact with bodily fluids containing infected cells, most often from 
mother  to  child  through  breast  milk  or  via  blood  transfusion.  After  prolonged  latency 
periods, approximately 3 to 5% of HTLV-1 infected individuals will develop either adult 
T-cell  leukemia/lymphoma  (ATL),  or  other  lymphocyte-mediated  disorders  such  as 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The genome of 
this  complex  retrovirus  contains  typical  gag,  pol,  and  env  genes,  but  also  unique 
nonstructural proteins encoded from the pX region. These nonstructural genes encode the 
Tax and Rex regulatory proteins, as well as novel proteins essential for viral spread in vivo 
such as, p30, p12, p13 and the antisense encoded HBZ. While progress has been made in 
the understanding of viral determinants of cell transformation and host immune responses, 
host and viral determinants of HTLV-1 transmission and spread during the early phases of 
infection are unclear. Improvements in the molecular tools to test these viral determinants 
in cellular and animal models have provided new insights into the early events of HTLV-1 
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infection. This review will focus on studies that test HTLV-1 determinants in context to 
full  length  infectious  clones  of  the  virus  providing  insights  into  the  mechanisms  of 
transmission and spread of HTLV-1. 
Keywords:  HTLV-1;  human  T-lymphotropic  virus  type-1;  transmission;  replication; 
determinants; animal models 
 
1. Introduction 
Human T-lymphotrophic virus type-1 (HTLV-1) is a member of the deltaretroviridae, a family of 
retroviruses which includes both simian T-lymphotrophic virus (STLV-1) and bovine leukemia virus 
(BLV). Based on epidemiology studies it has been estimated that approximately 15 to 20 million 
HTLV-1 carriers exist throughout the world, with endemic areas in Japan, the Caribbean, and Africa 
[1]. In these endemic areas there is a wide range of seroprevalance rates ranging from 0.1 to 30%. 
After prolonged latency periods (as long as 20 to 60 years), approximately 5% of HTLV-1 infected 
individuals will develop either adult T-cell leukemia/lymphoma (ATL), or other lymphocyte-mediated 
disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).  
HTLV-1 is spread through contact with bodily fluids containing infected cells. Contaminated whole 
blood  or  whole  blood  products  represent  the  most  common  form  of  HTLV-1  transmission  in  the 
United  States  of  America,  typically  from  sharing  of  needles  among  intravenous  drug  users  [2,3]. 
However the more natural route of HTLV-1 transmission is through infected mothers who breast feed 
their children resulting in the transfer of infected maternal lymphocytes to their infant [4]. Perinatal 
contamination of the fetus from infected maternal blood occurs, but does not represent a significant 
mode of HTLV-1 transmission [5]. The transmission of HTLV-1 through sex is a less efficient route of 
transmission,  however  male  to  female  transmission  via  semen  is  four-times  as  likely  to  lead  to 
transmission as female to male [6]. Transfusion of infected blood products remains a major public 
health concern, and is a principal reason for current blood donor screening procedures particularly in 
the United States, Japan, as well as other countries [7]. Japan has educated HTLV-1 infected mothers 
about  the  possible  risks  of  transmitting  HTLV-1  through  breast  feeding,  effectively  reducing 
transmission in endemic regions [8,9].  
Mechanisms of how HTLV-1 is transmitted between cells is an active area of research. HTLV-1 is 
poorly infectious as cell-free virus particles for most cell types. The exception appears to be dendritic 
cells which can be infected by cell-free HTLV-1 [10]. Well organized cell-to-cell contacts between 
HTLV-1-infected cells and uninfected T-cells have been described as ―virologic synapses‖ [11,12]. 
These  unique  contact  points  have  similar  features  as  immunologic  synapses  during  antigen 
presentation and appear to be virus-mediated, in part, through Tax [13]. As discussed in subsequent 
sections of this review, HTLV-1 p12/p8 expression increases T-cell contact through specific adhesion 
molecules and promotion of cellular conduits appears to enhance cell-to-cell viral transmission [14]. 
Recently more complex cell surface structures have been described that may protect HTLV-1 particles 
during  cell-to-cell  transfer.  Glycoprotein-rich  aggregates  on  the  surface  of  HTLV-1-infected  cells 
analogous to ―biofilms‖ suggest unique virus-mediated events may promote successful transmission Viruses 2011, 3                         
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between cell contacts [15]. Disruption of these structures inhibits cell-to-cell transmission by the virus. 
The  role  of  specific  viral  determinants  that  mediate  the  formation  of  these  glycoprotein  matrix 
structures remains to be determined.  
2. HTLV-1 Associated Diseases 
Adult  T-cell  leukemia/lymphoma,  in  its  acute  form,  is  an  aggressive  T-cell  malignancy  that 
typically occurs 20 to 30 years after infection with HTLV-1 [16]. Neoplastic disease associated with 
HTLV-1 is exhibited in a variety of clinical forms, but is characterized by a monoclonal population of 
T-cells that express CD3+/CD4+/CD8−/CD25+/HLA-DR+ cell surface markers [17–19]. Approximately 
1 to 5% of HTLV-1 infected patients eventually develop some form of ATL after a prolonged clinical 
latency period (Table 1).  
Clinically, ATL occurs in at least four different forms: (1) smoldering (2) chronic (3) lymphoma 
and (4) acute [17]. Patients afflicted with the acute form of ATL make up approximately 55 to 75% of 
all  ATL  cases  and  present  with  fever,  malaise,  skin  lesions,  lymphadenopathy,  leukocytosis  and 
hepatosplenomegaly [17]. To date, there a limited number of successful therapeutic protocols for ATL 
using standard chemotherapy treatments (reviewed in [20]). 
The prolonged and complex interactions between the host and the virus that lead to development of 
ATL  have  not  been  elucidated.  HTLV-1  infected  neoplastic  monoclonal  T-cells  originate  from 
polyclonal populations of infected T-cells [21]. Selective pressures such as the anti-HTLV-1 adaptive 
immune response of an infected individual promote an oligoclonal population of infected T-cells with 
survival  advantages  to  emerge  [22].  From  this  oligoclonal  population,  a  neoplastic  T-cell  clone 
emerges  typically  with  a  variety  of  somatic  genetic  mutations  [23,24].  HTLV-1’s  transacting 
transcriptional activator, Tax, plays a major role in the immortalization of these infected T-cells by 
altering distinct signaling or genetic events such as cell cycle control and DNA repair genes (reviewed 
in [25]). Tax and HBZ (below) appears to be required for initial immortalization of T-cells promoting 
the subsequent development of ATL and other lymphocyte-mediated disorders. In addition, evidence is 
accumulating that implicate the antisense encoded protein, HBZ or its RNA, in T-cell proliferation and 
perhaps maintenance of transformation [25,26]. 
In  1985,  Gessain  et  al.  [27]  reported  that  a  group  of  HTLV-1-seropositive  patients  in  French 
Martinique  suffered  from  a  neurodegenerative  disorder  called  tropical  spastic  paraparesis  (TSP)  
(Table 1). Osame et al. [28] subsequently described a similar clinical disorder in Japanese patients and 
termed it HTLV-1 associated myelopathy (HAM). The onset of HAM/TSP typically occurs in younger 
subjects infected with HTLV-1 and is more closely linked to the transfusion of HTLV-1 infected blood 
products, whereas ATL has been linked to transmission through breast milk of infected mothers [29]. 
A progressive chronic myelopathy, HAM/TSP mainly affects the thoracic spinal cord and patients 
often  present  with  urinary  incontinence,  ataxia,  intention  tremors  and  limb  paraparesis  [30].  The 
infiltration of HTLV-1 specific CD4+ and CD8+ T lymphocytes into the spinal cord leads to severe 
inflammation  from  production  of  proinflammatory  cytokines  such  as  IL-1,  IL-6,  IFN-γ,  and  
TNF-γ  [17].  Accumulation  of  proinflammatory  cytokines  leads  to  demyelination  and  lymphocytic 
meningomyelitis.  High  HTLV-1  antibody  titers  can  be  detected  in  the  CSF  [31].  The  detailed 
mechanism of HAM/TSP development like ATL has yet to be elucidated. However HTLV-1 proteins Viruses 2011, 3                         
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utilizing molecular mimicry or acting as autoantigens have been postulated as factors that contribute to 
the development of HAM/TSP [17,18]. Risk factors for the development of HAM/TSP such as high 
proviral loads have been linked with the development of HAM/TSP (reviewed in [30]).  
A number of other immune-mediated chronic inflammatory conditions are associated with HTLV-1 
infection (Table 1) [20,32,33]. However, it is less clear what specific role HTLV-1 infection plays in 
the  initiation  or  development  of  these  diseases.  HTLV-1-associated  arthropathy,  uveitis,  infective 
dermatitis, polymyositis, chronic respiratory disease, Sjogren’s syndrome, lymphadenitis, and certain 
acute myeloid leukemias have been associated with HTLV-1 infection (reviewed in [20]). It has been 
hypothesized that the dysregulation of the immune system in chronic HTLV-1 infection promotes 
diseases (reviewed in [34]). 
Table 1. Human T-lymphotrophic virus type-1 (HTLV-1) -associated diseases and syndromes. 
Disease or 
Syndrome  Clinical Characteristics and Pathologic Outcomes 
Adult T-cell 
leukemia/ lymphoma 
(ATL) 
 Four classifications based on clinical signs include: asymptomatic, pre-
leukemic, chronic smoldering, and acute  
 Clinical symptoms may include malaise, fever, lymphadenopathy, 
hepatosplenomegaly, hypercalcemia, lytic bone lesions, elevated lactate 
dehydrogenase, increased interleukin 2 receptor in serum, lymphomatous 
skin infiltrates, jaundice, weight loss, and various opportunistic infections, 
such as Pneumocystis carinii 
 Aggressive malignancy of T-lymphocytes, characterized by multiple 
distinct cell surface markers, including 
CD3+/CD4+/CD8−/CD25+/HLA−DR+ T-cells 
 Leukocytosis may include atypical cell morphology, multilobulated 
nucleus referred to as ―flower cells‖ 
 Diagnostic criteria include HTLV-1 seropositivity, leukocytosis, increased 
serum levels of IL-2 receptor and LDH, demonstration of neoplastic  
T-cells with polylobulated nuclear morphology (―flower cells‖), and 
clonally integrated HTLV-1 genomes within the chromosomes of 
neoplastic lymphocytes 
HTLV-1-Associated 
Myelopathy/ Tropical 
Spastic Paraparesis 
(HAM/TSP) 
 Spasticity lower extremities, hypereflexia, muscle weakness, and sphincter 
disorders, including dysfunction of the urinary bladder and intestines; 
clinically may overlap with multiple sclerosis 
 Progressive chronic myelopathy, with preferential damage of the thoracic 
spinal cord  
 Early lesion development characterized by infiltrates composed 
predominantly of CD4+ T-cells, and macrophages with detectable levels 
of HTLV-1 tax RNA in lesions 
 Characterized by multiple white matter lesions in both the spinal cord and 
the brain involving perivascular demyelination and axonal degeneration; 
rarely, cerebellar syndrome with ataxia and intention tremor 
 Late lesions (>4 years) predominantly CD8+ T-cells with less tax RNA  
 Cerebrospinal fluid contain high levels of proinflammatory cytokines, 
including IFN-, TNF-, IL-1, and IL-6, as well as increased numbers of 
activated lymphocytes Viruses 2011, 3                         
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Table 1. Cont. 
Disease or 
Syndrome  Clinical Characteristics and Pathologic Outcomes 
HTLV-1-associated 
Dermatitis 
  Chronic eczema with refractory Staphylococcus aureus or beta-hemolytic 
streptococcus infections 
  Described in Jamaican children as ―infectious dermatitis‖  
  Patients frequently develop HAM/TSP later in life and may have episodes 
of severe anemia 
Ocular Lesions    HTLV-1 infection associated in endemic regions with uveitis, 
keratoconjunctivitis sicca, and interstitial keratitis  
  Chronic course in children may result in retinal degeneration 
Inflammatory 
Arthropathy and 
Polymyositis 
  Chronic polymyositis associated with HTLV-1 may be presented with 
neuropathy, joint swelling, chest pain, and dyspnea 
  Japanese patients in regions endemic for HTLV-1 infection may present 
with chronic inflammatory arthropathy or polymyositis 
  Similar lesions have been reproduced in transgenic mouse and rat models 
3. Replication and Organization of the HTLV-1 Genome 
HTLV-1  is  a  single-stranded  diploid  RNA  virus  that  carries  genetic  information  for  structural 
proteins and enzymes (Gag, Env, reverse transcriptase (RT), protease, integrase (IN) (reviewed in [25]). 
The 3' end of the viral genome expresses alternatively spliced mRNAs encoding proteins from open 
reading frames (ORFs) I-IV (Figure 1). The RNA genome is in a ribonucleoprotein complex with the 
viral protein nucleocapsid (NC). Nucleocapsid along with capsid (CA) and matrix (MA) make up the 
three proteins produced from the Gag transcript. The env gene encodes for surface unit (SU) and 
transmembrane unit (TM) proteins. These proteins are responsible for binding and fusion to cellular 
membranes during viral entry. The enzymatic components of the retrovirus include integrase (IN), 
reverse transcriptase (RT) and protease (Pro). 
The genome of HTLV-1 is approximately 9032 nucleotides long and in its proviral (integrated 
form) contains two flanking long terminal repeat (LTR) sequences. The LTR’s of HTLV-1 are made 
up of 3 components, unique region 3' (U3'), repeated region (R) and unique region 5' (U5'). These  
cis-acting  sequences  are  critical  for  viral  gene  regulation  and  replication  including  coordinating 
transcription initiation and termination, splicing and polyadenylation of mRNA and strand transfer 
during reverse transcription [35,36]. The U3 contains three imperfect 21 base pair repeats named the 
Tax response element-1 (TRE-1). The TRE-1 binds multiple transcription factors and is an active site 
of chromatin remodeling (reviewed in [25,37]). 
The pX region contains the regulatory and non-structural genes of HTLV-1. The genes in the pX 
region are alternatively spliced and made from different initial sites. Open reading frame I and II 
encode p12 (p8), p30, and p13 [38,39]. Tax, the transacting transcriptional activator and Rex, the 
transporter of unspliced and single spliced viral RNA, are encoded from ORF-IV and III, respectively 
[35]. The HBZ gene is encoded from a complementary minus stranded RNA [40]. The expression of 
viral RNA from primary cells from infected subjects and cells transfected with HTLV-1 molecular 
clones indicates a two-phased pattern with tax/rex mRNA preceding expression of other transcripts and 
differential distribution of RNA species between cytoplasmic and nuclear compartments [41]. Viruses 2011, 3                         
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Figure 1. Human T-lymphotrophic virus type-1 (HTLV-1) genome, mRNA, and proteins. 
The HTLV-1 genome appears on top, the mRNA in the middle, and the protein species on 
the bottom. The numbers represent nucleotide positions of each exon splice acceptor and 
donor site. 
 
4.  Structural  Proteins  of  HTLV-1  and  Their  Influence  on  Viral  Particle  Assembly  and 
Transmission 
HTLV-1 Gag (group specific antigen) or p55 is produced as a single precursor polyprotein. The 
polyprotein is myristylated, post-translationally, and targeted for the inner lipid plasma membrane of 
the cell. At the inner membrane of the plasma membrane Gag is cleaved by viral proteases into its 
functional units: CA (p24), NC (p15) and MA (p19). Capsid interacts with itself to form the inner core 
of the virion. Nucleocapsid interacts with the genomic RNA inside the inner core of the virion. The 
proper spatial and temporal events of viral assembly and budding play a critical role in the ability of 
HTLV-1 to be transmitted from one cell to another (Figure 2).  
In contrast to HIV-1 Gag, the interaction of HTLV-1 MA appears to be independent of plasma 
membrane  phospholipid,  phosphatidylinositol-(4,5)-bisphosphate  [PI(4,5)P(2)]  used  by  HIV-1  in 
particle assembly [42]. HTLV-1 MA contains a PPPY domain that assists in virus budding by targeting 
cellular proteins Nedd4.1 and Tsg101 [43–45]. In addition to assisting in virus budding and assembly, 
MA appears to have a role in cell-to-cell transmission of the virus [46,47]. Utilizing an infectious 
molecular clone of HTLV-1 (ACH) [48], serine 105 of MA has been shown to be a target of the kinase 
ERK-2 influencing budding efficiency and viral particle release [47]. Thus, like other retroviruses, the Viruses 2011, 3                         
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phosphorylation of HTLV-1 L-domain proteins appears to be important in regulation of viral budding 
and thus cell-to-cell transmission.  
Figure  2.  HTLV-1  assembly  and  incorporation  of  viral  components  (left)  and  fully 
developed mature virion following budding from cell membrane (right). 
 
 
Using biochemical approaches and in vitro assays, HTLV-1 NC has been documented to function 
poorly as a nucleic acid chaperone and thus differs from other retroviruses such as HIV-1 [49,50]. In 
addition, HTLV-1 uses a C-terminal peptide region of NC to block the action of the host restriction 
factor ABOBEC3G [51]. Future studies using infectious molecular clones of HTLV-1 are needed to 
test the ability of specific mutations in the key NC motifs that mediate RNA binding and interactions 
with host restriction factors to understand how they influence the transmission and spread of HTLV-1 
in vivo.  
Protease is produced from ribosomal frame shifting initially as an immature form that is inactive 
until self cleavage activates the protease after viral budding [52,53]. Reverse transcriptase and IN are 
generated from proteolytic cleavage of the Gag/Pol precursor polyprotein. Reverse transcriptase is 
responsible for transcribing the RNA template and IN acts as a catalyst in the integration of the dsDNA 
viral template into the cellular genomic DNA [54].  
The HTLV-1 envelope protein (Env) is maintained among isolates and env variability ranges from 
1 to 8% [55–57]. HTLV-1 Env is a 488 amino acid protein synthesized as a polyprotein precursor 
(gp62), which is subsequently glycosylated and cleaved into two proteins, surface unit gp46 (SU) and Viruses 2011, 3                         
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transmembrane gp21 (TM) [58,59]. SU is required for entry into the target cell by mediating specific 
attachment to cellular receptors (below),  while the TM supports fusion between viral and cellular 
membranes to allow viral entry. 
HTLV-1 SU is a 312 amino acid protein. The C-terminal half of SU is highly antigenic and is 
recognized by serum antibodies from approximately 95% of HTLV-1 infected individuals [57]. A 
major target of neutralizing antibodies is focused on amino acids 187 to 196 of SU [57,60–62]. Early 
studies  using  site  directed  mutagenesis  demonstrated  functional  domains  within  SU  involved  in 
intracellular maturation, syncytium formation, and the association between SU and TM [57,60,63,64]. 
Subsequent development of a cell transmission assay allowed for separation of fusion events from 
infectivity events [65,66].  
Through a variety of techniques, specific protein motifs of HTLV-1 Env have been defined in 
terms of their ability to interact with cellular proteins important in cell fusion events. The HTLV-1 TM 
contains YSLI amino acid sequences that represent consensus YXXP motifs, known to interact with 
cellular  adaptor  protein  complexes,  and  a  PDZ-binding  motif  (ESSL)  at  the  C  terminus  of  Env. 
Alterations of the YSLI motif increased Env expression on the cell surface and increased cell fusion 
activity,  whereas  mutations  of  the  ESSL  motif  reduce  Env  expression  in  cells  [67].  The  human 
homologue  of  the  Drosophila  Dlg  tumor  suppressor  (hDlg),  a  scaffold  protein  important  at  cell 
adhesion sites, is a binding protein with HTLV-1 Env through a PDZ domain and is co-expressed in 
specific  regions  of  T-cell  contacts  [68].  RNA  interference-mediated  knockdown  of  Dlg1  reduces 
HTLV-1-mediated  syncytium  formation  apparently  by  interfering  with  Dlg1  induced  clustering  of 
GLUT1, a cellular receptor for HTLV-1 [69].  
Transient transfections of HTLV-1 env plasmids with specific mutations in the ACH molecular 
clone have verified key Env determinants in context to replicating virus [70]. Specific point mutations 
in env in ACH (ACH.75, ACH.95, and ACH.195) were compared for their ability to elicit antibody 
responses and proviral loads in a rabbit model of infection [71]. These mutations were within regions 
predicted to be important for binding of SU to the viral receptor based on syncytium assays or, in the 
case of ACH.195, in a major target for neutralizing antibody responses [60,62]. These mutations while 
replication  competent,  elicited  decreased  or  altered  antibody  responses  in  infected  rabbits  [71]. 
Mutations that affected Env at position 75 resulted in rabbits developing higher proviral loads than 
wild type ACH.1 and ACH.95 groups. These data support previous reports of the importance of these 
regions in SU (amino acids 187-196) in immunogenicity and viral spread in vivo.  
HTLV-1  SU  and  TM  form  as  heterodimers  at  the  surface  of  virions  and  are  responsible  for 
initiating binding, fusion with target cell and entry. The mechanism of action that facilitates cell-to-cell 
transmission of the HTLV-1 is not resolved, but recently several groups have reported data on three 
main cellular receptors: glucose transporter (GLUT-1), heparin sulfate proteoglycans and neuropilin-1 
[72–82]. Previous studies have shown GLUT-1 to be involved in envelope mediated cell-to-cell fusion 
[77]. Heparin sulfate proteoglycan binds virus particles on cell surfaces and facilitates entry [83]. In 
addition  to  being  the  main  receptor,  removal  of  heparin  sulfate  proteoglycan  from  primary 
lymphocytes significantly reduced binding of SU. Neuropilin-1 is part of the immunological synapse 
and  is  a  binding  partner  of  Env  [80].  Ectopic  expression  of  neuropilin-1  significantly  increased  
HTLV-1 Env-dependent syncytium formation [80]. Further studies will be required to identify specific 
envelope motifs that both alter receptor binding and influence viral transmission and spread in vivo.  Viruses 2011, 3                         
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5. Regulatory Proteins of HTLV-1 
5.1. Tax 
HTLV-1 Tax (Transcriptional Activator of pX region) is a 353 amino acid, 40 kDa phosphoprotein 
translated  from  a  doubly-spliced  mRNA  from  the  ORF  IV  (reviewed  in  [25,37,84].  Tax  is 
predominantly a nuclear protein, however it can translocate to the cytoplasm through use of a nuclear 
export protein [36,85,86]. Tax is responsible for initiating viral transactivation from the LTR of the 
provirus by binding the GC-rich regions of the TRE-1, within the U3 region of the LTR [87–90]. From 
the TRE-1, Tax can stabilize the CREB/ATF (activator of transcriptional factors) dimers, which are 
part of the transcriptional machinery needed for viral gene expression [91,92]. Tax also can recruit and 
bind CBP/p300 to the TRE-1. Phosphorylation of CREB by PKA leads to recruitment of CBP/p300 in 
normal cells; however in HTLV-1 infected T-cells Tax can bypass PKA-mediated phosphorylation of 
CREB. The ability of Tax to recruit and stabilize CREB-CBP/p300 and other factors like P/CAF 
(CBP/p300 associated factor) allows for efficient transcription of the provirus [93,94]. 
Tax can also bind TRE-2 in the LTR, which is located central and proximal to TRE-1. Tax recruits 
transcriptional co-activators like the aforementioned P/CAF and p300 (via KIX domain), Ets family 
transcription factors (Ets-1, -2, Elf-1, Tif-1) and c-Myb transcription factors to the TRE-2 region [95]. 
Tax can also bind the basic region of cellular basic leucine zipper transcription factors (bZIP), which 
aid in DNA binding. The presence of TRE-1 and -2 allows for Tax to mediate a number of processes 
and facilitate viral transcription bypassing cellular signals.  
Tax can activate expression of cellular genes including: (1) CREB/ATF, (2) NF-κB, (3) AP-1 and 
(4) SRF that influence cellular signaling pathways. These signaling pathways are responsible for the 
expression of multiple cytokines including: IL-1, -2, -2Rα, -3, -4, -6, -8, GM-CSF, and TNF α and β 
[96]. Transcription factors like c-Myc, c-Fos, c-Sis, Erg-1, c-Rel, and Lck are also influenced by 
expression of Tax [97]. Apoptosis and DNA repair genes like Bcl-XL, Bax and PCNA (proliferating 
cell nuclear antigen) respectively are also affected by Tax expression  [98–100]. The transforming 
ability of Tax is most likely attributable to its influence over the expression of these important cellular 
genes. The development of ATL serves as a model of how an oncogenic viral protein can indirectly 
lead to immortalization (IL-2 dependent proliferation) and transformation (IL-2 independent clonal 
expansion) of T-cells. 
The molecular mechanisms that lead to development of ATL have not been completely elucidated 
to date, however it is clear that Tax plays a pivotal role. Tax facilitates the translocation of NFκB into 
the nucleus and is responsible for activating transcription of genes that favor cellular proliferation and 
T-cell  survival.  Tax  can  bind  p50,  p52,  p65,  and  c-Rel  NFκB  family  members  [101,102].  Most 
notably, Tax can bind IκBα, an inhibitor of NFκB nuclear translocation. The association of Tax and 
IκBα destabilizes the IκBα/β/γ-NFκB complex and allows for NFκB translocation  [103]. The IκK 
complex is phosphorylated and subsequently ubiquinated and degraded by the proteosome. NFκB can 
then activate prosurvival and anti-apoptotic genes that promote cell survival and replication despite 
cellular  signals  that  might  favor  apoptosis.  The  promotion  of  cellular  replication  in  spite  of 
accumulation of genetic defects and apoptotic signals in the cell contributes to the transformation of 
lymphocytes and the development of ATL. Viruses 2011, 3                         
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While  the  role  of  Tax  in  cell  gene  expression,  proliferation,  and  transformation  have  been 
extensively studied, the role of Tax in viral transmission is less clear. Presumably, HTLV-1 would not 
be able to accomplish viral replication and spread without Tax function, but specific Tax determinants 
in viral transmission and spread are problematic to study. Infectious clones of the virus that have Tax 
mutations  would  fail  to  enhance  needed  viral  gene  expression  during  early  stages  of  cell-to-cell 
transmission. Interestingly, prostaglandins enhance viral expression via the HTLV-1 LTR through the 
protein kinase A signaling and Tax transactivates a promoter for cyclooxygenase 2, a prostaglandin 
synthetase, and induces PGE(2) expression in peripheral and cord blood mononuclear cells [104]. This 
reciprocal interaction has been postulated to promote viral transmission in vivo.  
Tax involvement in promoting cell adhesion and thereby cell-to-cell transmission has been reported. 
Significant correlation exists in cell lines comparing expression of HTLV-1 Tax and CCL22, a CCR4 
ligand in HTLV-1-infected T-cells, suggesting an active role of Tax in selective CD4+ T-cell viral 
transmission [105]. This conclusion is supported by transient Tax expression in an HTLV-1-negative 
T-cell line that induced CCL22 promoting CCR4 redistributed to cell contact points during in vitro 
transmission,  and  chemotaxis  assays.  Thus,  HTLV-1-infected  T-cells  may  selectively  attract 
CCR4+CD4+ T-cells [105]. Similarly, Tax induced enhancement of ICAM-1 on the surface of T-cells 
has been shown to facilitate the formation of viral synapses and therefore may contribute to T-cell 
tropism  and  viral  transmission  [106].  Interestingly  the  unique  cellular  microenvironment  during 
HTLV-1  milk-borne  transmission  may  favor  virus  expression.  Lactoferrin,  a  major  milk  protein, 
appears to enhance HTLV-1 replication by enhancing HTLV-1 LTR promoter activity (presumably in 
context  to  Tax  transactivation).  Conversely,  the  viral  infection  may  enhance  the  expression  of 
lactoferrin in the mammary gland environment [107].  
The  detailed  mechanisms  of  how  specific  Tax  induced  alterations  of  the  host  influence  viral 
transmission and spread wait specific testing of tax mutations in context to full length and infectious 
viral clones.  
5.2. Rex 
Rex is a 27 kDa phosphoprotein encoded by ORF III of the pX region [108,109]. Rex contains 
multiple functional domains including a RNA binding domain, nuclear localization sequence (NLS), 
nuclear export sequence (NES) and a multimerization domain [110]. 
Unlike Tax, Rex regulates viral gene expression only post-transcriptionally and is responsible for 
regulating expression of viral RNA. Rex facilitates nuclear transport of unspliced and singly spliced 
mRNAs (Gag, Env, Pol) into the cytoplasm [111]. The presence of the Rex response element (RxRE) 
in the U3/R 3’ LTR allows for Rex to bind all viral encoded RNAs [112]. Rex, like HIV-1 Rev, 
appears to utilize the CRM1/exportin pathway [113,114]. In addition, a 21 kDa Rex-like protein is 
produced in HTLV-1 infected cells, but lacks a nuclear localizing sequence (NLS) in the N terminus 
and when expressed in cells inhibit RNA shuttling [115]. The role of the 21 kDa form in the natural 
infection remains unclear.  
The essential role of Rex for viral infectivity has been confirmed using molecular clones with 
selectively  mutations  in  the  rabbit  model  [116].  A  Rex-deficient  HTLV-1  full  length  viral  clone 
(HTLVRex-)  was  used  to  provide  the  first  direct  evidence  that  functional  Rex  expression  is  not Viruses 2011, 3                         
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required for in vitro immortalization by HTLV-1, but was critical for optimal viral transmission in vivo 
[116]. These results suggest that defects in the ability of Rex to promote unspliced and single spliced 
RNA  to  traffic  are  important  for  optimal  viral  spread.  Construction  of  reciprocal  recombinant 
infectious molecular clones of HTLV-1 (ACH) and HTLV-2 (pH6neo) indicated that tax and rex genes 
do not contribute to transformation tropisms preferences [117]. A more refined study of Rex using 
point or specific motif deletions in context to infectious clones will be required to understand the 
detailed mechanism of how Rex influences viral transmission.  
6. Nonstructural Proteins of HTLV-1: Essential Role in Viral Spread and Transmission 
The pX region of the HTLV-1 genome also contain ORF I and II, which encode four nonstructural 
proteins (Figure 1). Alternative splicing of ORF I and II yields p27, p12, p30 and p13 [38,118,119] All 
of these spliced mRNA’s share a common 1st exon nucleotide (nt.) 1-119 in the R region of the  
5' LTR. Doubly spliced mRNAs encode 2nd exons that start at either nucleotide 4641 or 4658 and end 
at nucleotide 4831. There are numerous splice acceptor sites for the alternatively spliced mRNAs of 
ORFs I and II. The 3rd exons for doubly spliced mRNAs such as p27 and p30 have splice acceptor 
sites at nt. 6383 and 6478, respectively. The second exons for singly spliced mRNAs such as p12 and 
p13 have splice acceptor sites at nt. 6383 and 6875, respectively. 
Initial studies examining the importance of the nonstructural genes suggested they were dispensable 
in vitro [120], however recent studies have supported the role of these nonstructural genes in the 
transmission and spread of the virus in vivo [14,116,121–126]. The nonstructural genes encoded from 
ORFs I and II are vital for viral infectivity, maintenance of the virus life cycle and proviral loads in vivo, 
as well as host cell activation and regulation of viral gene transcription [121–123,127–132]. The genes 
from ORF I and II can be detected in HTLV-1 positive cell lines and in patients (asymptomatic, ATL 
and  HAM/TSP  patients)  [118,133].  Even  though  detecting  the  actual  proteins  has  been  difficult, 
mRNA  has  been  detected  by  RT-PCR  and  QC-PCR  [119].  Patients  also  possess  antibodies  and 
cytotoxic T-cells (CTLs) directed against these proteins [134,135]. ORF I genes appear to be expressed 
100–1000 times less than ORF III and IV genes and ORF II genes are expressed 500–2500 times less 
than  ORF  III  and  IV  genes  [136].  The  huge  discrepancy  in  expression  might  explain  why  these 
proteins are difficult to detect and suggest that they might be regulated differently than Tax and Rex. 
6.1. p12 and p8 
HTLV-1 p12 is a 99 amino acid hydrophobic rich protein, rich in leucine (32%) and proline (17%) 
[119]. p12 has several predicted amino acid regions or motifs which are responsible for a number of its 
important functions in the cell. p12 contains two putative transmembrane domains (amino acids 12 to 
30; 48 to 67) and two leucine zipper motifs [137]. The predicted leucine zipper motifs form α helices 
in the protein. Together the putative transmembrane domains and the leucine zipper motifs contribute 
to the ER localization and dimerization of p12 [138,139]. In addition to the aforementioned motifs p12 
contains four putative SH3 binding (PXXP) motifs and one conserved PSLP(I/L)T motif [140]. The 
proline rich Src homology-3 (SH3) motifs are predicted to be responsible for binding cellular signaling 
proteins. The first (amino acids 8 to 11) and third (amino acids 70 to 74) SH3 binding motifs are 
highly conserved among different HTLV-1 strains. The conserved PSLP(I/L)T motif is homologous to Viruses 2011, 3                         
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the calcineurin binding PxIxIT motif present in Nuclear Factor of Activated T-cells (NFAT) [141]. 
This sequence has the capacity for calcineurin binding in the cell. Calcineurin and NFAT represent a 
few of the many Ca
2+ signaling proteins, transcription factors, and ER/cis-Golgi associated proteins in 
the cytoplasm that p12 interacts with to influence gene expression infected T lymphocytes. 
In  addition  to  calcineurin  and  NFAT,  calreticulum  and  calnexin  bind  p12  and  mediate  Ca
2+ 
regulated pathways in the cell. These ER associated proteins are involved in regulating Ca
2+ storage 
and  regulating  Ca
2+  signaling,  respectively.  Calreticulum  is  a  chaperone  protein  responsible  for 
retaining the MHC class 1 molecule folded in the ER along its maturation pathway. Calnexin assists in 
proper protein folding of glycoproteins that enter the secretory pathway. The modulation of NFAT 
activation and thus T-cell signaling is accomplished through interactions between Ras/MAP kinase by 
p12. When stimulated by phorbol ester and PMA, p12 can activate NFAT [128]. p12 accomplishes this 
through releasing intracellular Ca
2+ from ER storage and by increasing Ca
2+ entry into the cell [142]. 
HTLV-1 p12 has numerous effects on cell signaling when expressed exogenously. Exogenously 
expressed p12 can affect T-cell signaling as well. p12 expressed exogenously can bind IL-2R β and γ 
subunits [143]. IL-2 expression is increased via NFAT activation in a Ca
2+ dependent manner in Jurkat 
and primary T lymphocytes. In turn, this leads to a reduced dependency on IL-2 for T-cell activation in 
the presence of p12 [144]. In addition to Ca
2+ signaling related proteins, p12 can also bind vacuolar 
H+-ATPase and immature peptides of MHC class I, which leads to their proteosomal degradation 
[145,146]. The proteosomal degradation of MHC class I molecules is predicted to lead to a lower 
percentage of viral peptides being expressed on the surface of infected cells in the context of an MHC 
class I  molecule  [147].  With decreased presentation of viral  peptides on MHC class I  molecules, 
infected cells may avoid detection from the HTLV-1 specific adaptive immune response. To test the 
influence of ORF1 expressed proteins in cell transmission, an established T-cell line immortalized with 
an HTLV-1 molecular clone, which does not express ORF 1 mRNA, was transduced with a lentivirus 
vector expressing p12 [148]. In this study, p12 expression conferred a selective growth advantage  
in vitro and increased the colony formation of human T-cells in soft-agar assays. IL-2 stimulation and 
p12 expression significantly increased the rate of syncytium formation, suggesting a novel role for  
IL-2 signaling and Jak activation in HTLV-1 virus transmission [148].  
HTLV-1 p12 has been demonstrated to be proteolytically cleaved to create a smaller protein, p8. 
This  protein  apparently  serves  a  different  role  and  acts  to  increase  T-cell  contact  through  LFA-1 
clustering thereby enhancing the cellular contacts among T-cells to enhance viral transmission, while 
anergizing T-cell signaling [14]. The ability of p8 to decrease T-cell activation is likely mediated 
through inhibiting proximal T-cell receptor signaling at the immunological synapse where it decreases 
phosphorylation of key signaling proteins in a LAT-dependent mechanism [14,149].  
The  ability  of  p12  to  induce  LFA  clustering  on  infected  T  lymphocytes  was  previously 
demonstrated and hypothesized to increase the efficiency of cell-to-cell spread of the virus [127]. The 
processing of p12 into p8 may account for the influence of the ORF1 encoded proteins on LFA-1 
clustering on the cell surface and the formation of cellular conduits [14]. Equally as plausible is the 
ability  of  p12  to  induce  calcium-mediated  LFA-1  clustering  on  the  surface  of  T-cells,  a  known 
mechanism of LFA-1 functional activation [150–152].  
The first evidence that pX ORF1 was important for viral transmission was demonstrated in the 
rabbit model using a splice acceptor site mutant of the ACH infectious molecular clone [121]. Ablation Viruses 2011, 3                         
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of the acceptor splice site through the deletion of four nucleotides was associated with a reduction of 
viral infectivity in vivo [121] and in vitro in non-stimulated T-cells [123]. The deletion of this p12 
acceptor splice site would also introduce a frame shift in the HBZ antisense ORF, resulting in the 
deletion of the last 24 amino acids of HBZ [153]. However the replication capacity of subsequent 
specific HBZ mutants in context of molecular clones did not result in complete reduction of infectivity 
as observed in ORF1 splice mutants [154]. Thus, the rabbit model was able to detect selected HBZ 
mutations and demonstrated that these were different in viral spread compared to ORF 1 mutants. The 
alteration of ORF I splice sites did not disrupt the expression of Tax, Rex, and structural proteins such 
as Env in expression in ACH.p12 [128]. A recent study tested a variety of HTLV-1 mutant molecular 
clones for their ability to replicate in dendritic cells and in vivo in rabbits and macaques [126]. In this 
study, mutations to  ablate  p12, p30, and  HBZ were introduced in the  ClaI/SalI cassette from the 
HTLV-1 molecular clone pBST that encompasses the orf-I and the orf-II. The molecular clone pACH 
was cleaved at the ClaI/SalI to generate the backbone for the construction of all viral mutants. Rabbits 
inoculated intravenously with these mutant clones had reduced viral loads at 16 weeks post inoculation 
before recovering to ―wild type‖ control level. Dendritic cell cultures from macaques infected with 
these mutant clones had reduced viral replication parameters suggesting the importance of this cell 
type in early viral transmission [126]. Small groups of macaques inoculated with these same mutant 
molecular clones also exhibited limited viral expression [126] confirming the importance of p12/p8 
and p30 expression for viral transmission. 
6.2. p13 
HTLV-1  pX  ORFII  encodes  for  p13  from  a  singly  spliced  mRNA  [155].  The  viral  protein  is 
predominantly  localized  in  the  nucleus  and  mitochondria  of  transfected  cells  [133,139,156,157]. 
Ectopic expression of p13 affects structure and disrupts the inner membrane potential of mitochondria 
[158,159]. The mitochondrial targeting signal (MTS) of p13, which allows the viral protein to target 
the  mitochondria,  is  a  predicted  α-helix  that  is  arginine  rich  and  amphiphatic  [157,158].  The 
incorporation of p13 into the inner mitochondrial membrane causes morphological changes such as 
swelling  and  a  loss  of  inner  membrane  potential  ()  [158].  These  alterations  of  the  inner 
mitochondrial membrane change energy production, redox status and induce apoptosis in cells [158]. 
p13  influence  on  cell  proliferation  in  vitro  is  dependent  on  the  stage  of  cell  transformation.  The  
viral protein suppresses Ras-dependent tumor explants in mice likely through modulation of cellular 
metabolism [160]. The ectopic expression of p13 causes Jurkat T-cells to be sensitive to caspase-
dependent,  ceramide-  and  FasL-induced  apoptosis.  A  farnesyl  transferase  inhibitor  that  prevents  
post-translational modification of Ras blocks this suppressive effect of p13 [161]. Importantly, an 
infectious molecular clone of a HTLV-1 with a selective mutation that prevents the translation of p13, 
without affecting RNA splicing, failed to establish viral infection in a rabbit model [162]. Interestingly, 
primary  T-cells  that  express  p13  are  activated,  while  causing  transformed  cells  to  be  sensitive  to 
reactive oxygen species [163]. Collectively these studies indicated that p13 has the ability to modulate 
cell survival via Ras-mediated cell signaling and has an essential role early virus transmission and in 
virus persistence. p13 interacts with farnesyl pyrophosphate synthase (FPPS), which is involved with 
synthesis  of  FPP  substrate  and  is  required  for  prenylation  of  Ras  and  subsequent  activation  of  Viruses 2011, 3                         
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Ras  [164].  This  interestingly  resembles  the  action  of  a  protein  in  bovine  leukemia  virus,  G4  
(a nonstructural protein) which acts in a similar fashion as p13 in the mitochondria [165]. 
6.3. p30 
HTLV-1 p30 is expressed predominantly in the cell nucleus and found primarily in the nucleolus 
[139]. In the nucleolus, p30 interacts with the large ribosomal subunit L18a which modulates internal 
initiation of translation [166]. The bipartite NLS of p30 is contained between amino acids 71-98 [156]. 
In addition to this bipartite NLS, p30 contains a localization/retention domain at amino acids 73-78 
and 91-98 [166]. p30 also contains serine and threonine rich domains that share partial homology to 
the POU transcription family members activation domains such as OCT-I/II, Pit-1, and POU-1 [133].  
p30 decreases reporter gene activity of HTLV-1 LTR and CRE driven reporter genes [132]. The 
transcriptional activity of p30 may be in part determined through its ability to compete with CBP/p300 
with Tax via the KIK domain [130]. Competition between Tax and p30 for CBP/p300 complex on the 
TRE determines if there is Tax mediated viral gene activation or p30 mediated viral gene repression 
[130].  p30  also  alters  viral  gene  expression  post-transcriptionally  via  its  ability  to  bind  Tax/Rex  
mRNA  in  the  nucleus  and  prevent  its  exit  into  the  cytoplasm  for  translation  [167,168].  This  
post-transcriptional effect of p30 is likely mediated via a ternary ribonucleoprotein complex on select 
viral transcripts [169]. p30 appears to bind specifically to Tax/Rex mRNAs expressed from molecular 
clones and not cDNA [167,170]. Jurkat T-cells transduced with a lentiviral vector expressing p30 
caused a  delay at the G2-M  phase of the cell  cycle  [171]. These  data suggest that p30 acts in a 
prosurvival role in the face of genotypic mutations induced by HTLV-1 replication and Tax expression 
[171]. Ectopically expressed p30 binds to cellular ataxia-telangiectasia mutated (ATM) and REGγ  
(a  nuclear  20S  proteasome  activator)  [172].  In  conditions  of  genotoxic  stress  p30  expression  was 
associated with reduced levels of ATM and increased cell survival. These data suggest that HTLV-1 
p30 interacts with ATM and REGγ to increase viral spread by facilitating cell survival. In addition, 
interaction  of  p30  with  Myc-Tip60  complex  modifies  Tip60  mediated  transcription  and  may  
promote  cellular  transformation  [173].  HTLV-1  p30  has  been  recently  demonstrated  to  inhibit 
conservative  homologous  DNA  repair  by  targeting  the  MRN  complex,  which  would  favor  error  
prone  non-homologous  end  joining  DNA  repair  pathway  and  perhaps  increase  the  risk  of  cell 
transformation [174]. 
Early studies which examined molecular clones that failed to express ORF-II mRNA or produced 
truncated forms of p30 indicated that ORF II was not required for virus replication in cell culture or  
in  vitro  T-cell  transformation  [175].  In  contrast,  our  lab  has  demonstrated  that  HTLV-1  
molecular clones that lack p30 expression do not establish infection in a rabbit model of HTLV-1 
infection [124]. In conclusion, p30 is a multifunctional protein important in multiple transcriptional 
and post-transcriptional phases of HTLV-1 replication and appears to be required for the virus to 
establish a productive infection in the host. 
6.4. HBZ 
HTLV-1 expresses two mRNA products from the 3' LTR of the complementary strand of the virus 
genome of 2.6 kb and 2.9 kb in length [176]. The protein produced from these anti-sense transcripts Viruses 2011, 3                         
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has been named HTLV-1 bZIP factor or HBZ. HBZ is composed of 209 amino acids and contains  
a  NLS,  amino  terminal  transcriptional  activation  domain  and  a  carboxyl  terminal  leucine  zipper  
motif [177,178].  
Recent in vitro and in vivo studies have elucidated the function of HBZ in the virus life cycle.  
In  vitro  studies  demonstrated  that  the  carboxyl  terminal  truncations  of  HBZ  did  not  affect  virus 
replication  and  immortalization.  Deletion  of  HBZ  expression,  however,  from  infectious  molecular 
clones of HTLV-1 resulted in decreased in proviral load and antibody responses in the rabbit model 
[154] and knock down of HBZ expression reduces tumor growth in a mouse model of ATL [179]. The 
inability of HTLV-1 to persistently infect rabbits without HBZ expression is most likely attributed to 
the lost of interactions between HBZ and important viral and cellular proteins. HBZ has been shown to 
interfere with Tax mediated viral transactivation of the LTR in a TRE dependant manner [177]. HBZ 
can form heterodimers with CREB-2, which prevents recruitment to the TRE and CRE transcriptional 
regions [177]. This implies that HBZ might be a negative regulator of viral transcription. 
In  addition  to  CREB-2,  HBZ  can  form  dimers  with  other  proteins,  which  are  important  for 
transcription. HBZ interacts with JunD, JunB and c-Jun [153,180]. Dimerization between HBZ and 
JunD  or  JunB  increases  transcriptional  activity  of  both  transcription  factors  [153,180].  However, 
dimerization  between  c-Jun  and  HBZ  results  in  a  decrease  in  c-Jun  transcriptional  activity  [153]. 
Studies have also shown HBZ can impair the DNA binding of AP-1, another important transcription 
factor [181]. Mice transgenic for HBZ have increased proliferation of CD4+Foxp3+ T(reg) cells but 
have  reduced  ability  to  suppress  other  lymphocyte  proliferation  perhaps  through  interaction  with 
Foxp3 and NFAT [182]. Collectively, these studies have elucidated potential findings of HBZ in the 
context of the HTLV-1 life cycle; however more studies are required to completely understand the role 
of HBZ in the natural infection and in the pathogenesis of HTLV-1-mediated diseases.  
7. Animal Models to Evaluate Viral Determinants of HTLV-1 Transmission and Spread 
Since the discovery of HTLV-1, a number of animal models of HTLV-1 transmission and spread 
have provided fundamental information about viral and host determinants of infection [183]. Rabbits 
[184,185], some nonhuman primates [186,187] and rats [188,189] can all be infected with HTLV-1 
and have been utilized to monitor the virus spread, determine immune responses against the infection 
and  in  the  development  of  vaccines  against  the  viral  infection.  These  animal  models  of  HTLV-1 
infection or disease have been recently reviewed [183]. In evaluating an appropriate animal model of 
HTLV-1 infection or disease, it is important to differentiate animal models that test individual genes of 
the virus from those that place the gene under the typical control of HTLV-1 in context of a complete 
genome.  To  accurately  model  HTLV-1  determinants  of  viral  transmission  and  spread,  the  model 
system should: (1) be tested in context of the complete viral genome, (2) test mutant viral clones 
concurrent with positive controls that demonstrate infectivity with parameters (e.g., proviral loads) 
similar to those used to monitor humans infected with the virus,  (3) reproducibly elicit persistent 
infections  with  widespread  distribution  of  the  virus  as  seen  in  humans  infected  with  HTLV-1,  
and  (4)  ideally  be  economical  and  easily  monitored  e.g.,  animals  with  blood  volumes  that  allow 
multiple serial measurements.  Viruses 2011, 3                         
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Rabbits have been used extensively as a model of HTLV-1 infection in humans because of the ease 
and consistency of transmission of the viral infection in this species (Figure 3). Infectivity of rabbits 
was first demonstrated in the mid-1980s using intravenous inoculations of the MT-2 cell line [184], a 
T-cell leukemia cell line established from a patient with ATL, and with the Ra-1 cell line [190], a 
rabbit lymphocyte cell line derived from co-cultivation of rabbit lymphocytes with MT-2 cells. These 
early  studies  verified  routes  of  transmission  (e.g.,  blood,  semen,  milk)  for  the  virus  infection  
[191–196]. Importantly, studies using the rabbit model of HTLV-1 have provided accurate data to 
estimate the number of cells capable of transmitting the virus infection [193] and effective means to 
prevent the transmission of the virus [62,193,197–199]. Rabbit-based studies defined the sequential 
development of antibodies against the virus infection [200]. Immunization of rabbits with synthetic 
peptides verified immunodominant epitopes of the viral envelope protein (Env) [201,202] and defined 
regions of Env important for antibody dependent cell-mediated cytotoxicity [203].  
Figure 3. Rabbit model of HTLV-1 transmission demonstrates a reproducible system to 
produce persistent infections with widespread distribution of the virus similar to humans in 
an economical and easily monitored  model. Example showing inoculation of HTLV-1-
transformed  cell  line  (R49)  with  ACH  proviral  clone  [204].  Determinants  of  viral 
transmission and spread can be measured in context of the complete viral genome with the 
ability  to  test  mutant  viral  clones  concurrent  with  positive  controls  that  demonstrate 
infectivity with parameters (e.g., proviral loads). 
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Infectious molecular clones of HTLV-1 were first developed in the mid-1990s [48,205,206] and 
opened  the  door  for  testing  viral  determinants  in  context  to  the  viral  infection  in  vivo  [207]. 
Subsequently,  ACH  clones  with  mutations  within  the  open  reading  frames  encoding  the  HTLV-1 
accessory proteins, p12, p13, and p30, were generated [175], and used in rabbits to demonstrate the 
necessity of these accessory proteins for establishment of infection and maintenance of proviral loads 
[121,122,124,162]. The roles of Rex and HBZ in viral transmission and spread have been tested using 
the ACH clone in rabbits [116,154]. Using ACH wild type virus immortalized rabbit T-cells in an 
intravenous  infection  model,  HTLV-1  was  found  to  accumulate  in  primary  lymphoid  and  
gut-associated lymphoid compartments in  rabbits  and  was associated with  an  early  lymphocytosis 
[204]. These data are consistent with a variety of human studies that support emerging evidence that 
HTLV-1 promotes lymphocyte proliferation preceding early viral spread in lymphoid compartments to 
establish and maintain persistent infection. Immunosuppressive treatment prior to HTLV-1 infection in 
the rabbit model (modeling case reports in human transplant patients exposed to contaminated blood 
products) reveal enhanced early viral expression compared to untreated HTLV-1-infected rabbits, and 
altered long-term viral expression parameters. However, this same treatment one week post infection 
diminished HTLV-1 expression for greater than 10 weeks, interfering with typical viral loads [208]. 
This  type of  study extends  studies of chronically infected humans  that indicate that immunologic 
control is a key determinant of viral persistence [209–211]. The rabbit model clearly demonstrates the 
sequential  control  during  early  HTLV-1  spread  and  offers  a  tractable  model  to  test  therapeutic 
strategies during mucosal transmission.  
Mouse models of ATL, which typically are focused on xenografts to test anti-cancer compounds or 
transgenic mice to test the properties of individual oncoproteins, have been recently reviewed [212]. 
As  a  complete  genome  inoculated  in  a  cell-associate  form,  HTLV-1  consistently  infects  rabbits 
[184,185], some non-human primates [186,187], and to a lesser extent rats [188,189]. Viral transmission 
in mice has produced inconsistent infections with limited virus expression in tissues and thus do not 
provide a reliable system to test virus spread in the host [213–216]. Non-human primates have been 
infected with HTLV-1 and a number of species have natural infections with various strains of simian 
T-lymphotropic virus infection type 1 [217–219]. The squirrel monkey has been successfully infected 
with HTLV-1 and has been used for HTLV-1 vaccines [24,220–222]. In a limited study, HTLV-1 
mutant molecular clones were tested for their ability to replicate in dendritic cells and in vivo in rabbits 
and  macaques  [126].  Some  strains  of  rats  have  been  utilized  as  a  model  of  HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/ATL), the neurologic disease associated with the viral 
infection [189,223–227]. While rats have been used to test the role of cell-mediated immunity to the 
infection [224,228], the reproducibility of the infection has been questioned [188]. Sheep infected with 
bovine leukemia virus are a reliable model of lymphoma and have provided knowledge of viral genetic 
determinants of viral spread in vivo [229–231].  
Experimental  infection  of  F344  rats  with  HTLV-1  was  first  established  in  1991  [189]. 
Subsequently,  differences  in  the  response  of  various  rat  strains  to  HTLV-1  infection  were 
demonstrated  [188,227,232].  Wistar-King-Aptekman-Hokudai  (WKAH)  rats  develop  spastic 
paraparesis  with  degenerative  thoracic  spinal  cord  and  peripheral  nerve  lesions  several  months 
following inoculation [227,232]. The neurologic lesions of WKAH-infected rats were predominantly 
characterized by macrophage infiltrates, which differs from that seen in humans [233].  Viruses 2011, 3                         
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Experimental  HTLV-1  infection  has  produced  persistent  infections  in  several  species  of  
non-human primates inoculated with MT-2 cells, Ra-1 cells, or autologous HTLV-1-infected cell lines 
[234–236]. HTLV-1 immortalized cell lines from Squirrel monkeys have been used in this species to 
document peripheral lymphocytes, spleen and lymph nodes as major reservoirs for the virus during the 
early phase of infection [221,237,238]. HTLV-1 infection in squirrel monkeys appears to be dependent 
on early reverse transcription of the virus genome, followed by clonal expansion of infected cells [24]. 
HTLV-1 inoculated rhesus macaques appear to develop a higher incidence of arthritis, uveitis, and 
polymyositis [239]. In addition, pig-tailed macaques that died naturally at 35 to 82 weeks post-inoculation 
with ACH HTLV-1 molecular clone HTLV-1 exhibited lymphopenia, arthropathy, and diarrhea [240]. 
While a promising model species, the cost of maintenance of non-human primates have limited more 
extensive use of this model to test HTLV-1 determinants of virus transmission. 
8. Conclusions 
Human T-lymphotropic virus type-1 (HTLV-1) has evolved to spread from mother to child through 
breast milk or via blood transfusion and is associated with adult T-cell leukemia/lymphoma (ATL), and 
a  variety  of  lymphocyte-mediated  disorders  such  as  HTLV-1-associated  myelopathy/tropical  spastic 
paraparesis (HAM/TSP). The complex retrovirus contains typical gag, pol, and env genes, but also 
unique  nonstructural  proteins  encoded  from  the  pX  region  that  are  essential  for  viral  spread  
in vivo. Infectious molecular clones of the virus have allowed testing of viral genes in the transmission 
and  spread  of the virus. Further studies,  however,  of specific  functional motifs of  key  viral gene 
products in context to mucosal transmission are needed to determine the interplay of host defenses and 
these viral determinants in viral transmission and spread of HTLV-1. 
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